G1 Therapeutics

G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

G1 Therapeutics excels in Q4 with Cosela sales surge and optimistic 2023 outlook

G1 Therapeutics delivered strong financial results in Q4 2022, driven by the impressive performance of Cosela in the small cell lung cancer market. Despite organizational changes to conserve capital, the company remains focused on growth and innovation. With a solid cash balance projection for 2023 and a growing customer base, G1 Therapeutics is poised for continued success.

G1 Therapeutics reports robust Q1 performance and optimistic growth outlook

G1 Therapeutics demonstrated strong financial performance and commercial growth in Q1 2023, with COSELA showing promising results and a positive outlook for the future.
While facing challenges related to potential drug interactions, the company is well-positioned to capitalize on opportunities through upcoming data readouts and strategic decisions.
Investors can be optimistic about G1 Therapeutics' continued progress, supported by a solid financial foundation and a focus on maximizing COSELA's potential.

G1 Therapeutics reports resilient Q2 performance amidst challenges and opportunities

G1 Therapeutics delivered a strong financial performance in Q2 2023, showcasing resilience and strategic financial management amidst challenges.
The company's focus on advancing its clinical pipeline and securing survival results in early 2024 positions it for future growth and value creation.
While facing challenges such as a chemotherapy shortage and operational efficiency, G1 Therapeutics maintains stability and confidence in its financial outlook.
Opportunities lie in capitalizing on COSELA sales growth, advancing clinical programs, and leveraging financial flexibility for sustained growth and innovation.

G1 Therapeutics overcomes supply challenges, eyes growth in oncology

G1 Therapeutics exhibited resilience in revenue growth despite challenges with COSELA's market supply, showcasing operational strength.
The company's strong financial position and cost management efforts bode well for sustainable growth and value creation.
Exciting opportunities in clinical trials and market expansion present avenues for future success and competitive positioning in the oncology sector.

G1 Therapeutics excels in Q4 2023, poised for growth ahead

G1 Therapeutics demonstrated strong performance in Q4 2023 with notable revenue growth and expense management.
COSELA's market share and promising trial results highlight strengths in the product portfolio.
While challenges like trial result anticipation and cost efficiency persist, opportunities for growth and optimization are evident.
Overall, G1 Therapeutics shows promise with a healthy cash position and positive sales guidance for 2024.

G1 Therapeutics reports strong Q1 earnings and diversifies revenue streams

G1 Therapeutics delivered robust financial results, showcasing growth in revenue and cost management improvements in Q1 2024.
While facing challenges in managing expenses and advancing clinical trials, the company remains optimistic about revenue guidance and market opportunities.
With a solid cash position and strategic partnerships, G1 Therapeutics is well-positioned to drive future growth and innovation in the oncology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

G1 Therapeutics, Inc. is a commercial-stage oncology firm focused on the research and marketing of next-generation anticancer treatments.

RESEARCH TRIANGLE PARK, N.C., Oct. 28, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call to provide a corporate and financial update for the third quarter of 2020 on Wednesday, November 4, 2020 at 4:30 p.m. ET.

G1 Therapeutics to Provide Third Quarter 2020 Corporate and Financial Update on November 4, 2020

RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that four presentations highlighting the myelopreservation benefits of trilaciclib and its ability to reduce the need for reactive interventions will be featured at the North America Conference on Lung Cancer (NACLC) being held October 16-17. Trilaciclib is a first-in-class investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy.

G1 Therapeutics to Present Data on Trilaciclib at North America Conference on Lung Cancer (NACLC)

- Mark Velleca, M.D., Ph.D., G1’s first Chief Executive Officer, to serve as senior advisor and remain member of the G1 Board of Directors

G1 Therapeutics Announces Chief Executive Officer Succession Plan

RESEARCH TRIANGLE PARK, N.C., Sept.  14, 2020  (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:  GTHX ), a clinical-stage oncology company, today announced that two presentations highlighting data on the investigational oral CDK4/6 inhibitor lerociclib, including updated findings from a Phase 2 trial of lerociclib in combination with fulvestrant in HR+, HER2- advanced breast cancer patients, will be featured at the ESMO Virtual 2020 Congress being held from September 19-21.

G1 Therapeutics to Present Data on Oral CDK4/6 Inhibitor Lerociclib at European Society for Medical Oncology (ESMO) Virtual 2020 Congress

RESEARCH TRIANGLE PARK, N.C., Sept.  02, 2020  (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:  GTHX ), a clinical-stage oncology company, today announced that the company will participate in the following investor conferences in September 2020:

G1 Therapeutics to Participate in Four Investor Conferences in September 2020

BeyondSpring

Karyopharm Therapeutics

UroGen Pharma

Oncology Stocks Area Trading Materially Lower The Last 2 Months

Of a pool of 26 oncology stocks we track, with 1 exception, all (literally 25 of 26) are trading materially lower from the third week of June 2020.

Oncology Stocks Are Trading Materially Lower The Last 2 Months

- PDUFA action date of February 15, 2021 assigned by U.S. Food and Drug Administration  - Priority Review for trilaciclib is based on positive data from three randomized clinical trials showing robust myelopreservation benefits  - G1 launching expanded access program (EAP) for patients with small cell lung cancer in the U.S.

G1 Therapeutics Announces Acceptance and Priority Review of NDA for Trilaciclib for Patients with Small Cell Lung Cancer

G1 Therapeutics' (GTHX) CEO Mark Velleca on Q2 2020 Results - Earnings Call Transcript

- Submitted New Drug Application (NDA) for trilaciclib in small cell lung cancer (SCLC)  - Co-promotion agreement with Boehringer Ingelheim for U.S. trilaciclib launch  - Partnership for trilaciclib in China and global out-licensing of lerociclib net a combined $40 million in upfront payments, up to $486 million in milestone payments, plus potential royalties  - Secured $100 million credit facility to support trilaciclib development and commercialization  - Increasing cash guidance for FY 2020 to $185-$200 million at year end  - Management to host webcast and conference call today at 5:00 p.m. ET

G1 Therapeutics Provides Second Quarter 2020 Corporate and Financial Update

RESEARCH TRIANGLE PARK, N.C., Aug.  04, 2020  (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:  GTHX ), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will present company updates at two investor conferences in August 2020:

G1 Therapeutics to Participate in BTIG and Wedbush Healthcare Conferences in August 2020

RESEARCH TRIANGLE PARK, N.C., July  29, 2020  (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:  GTHX ), a clinical-stage oncology company, today announced that it will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2020 on Wednesday, August 5, 2020 at 5:00 p.m. ET.

G1 Therapeutics to Provide Second Quarter 2020 Corporate and Financial Update on  August 5, 2020

- G1 to receive $20 million upfront payment, sales royalties and potential milestone payments of up to $290 million for commercialization of lerociclib in the U.S., Europe, Japan

G1 Therapeutics Announces License Agreement for Lerociclib

- Partnership leverages Boehringer Ingelheim’s oncology expertise to lead trilaciclib SCLC launch sales engagements  - G1 to retain full development and commercialization rights and book revenue for trilaciclib  -New Drug Application (NDA) for trilaciclib submitted in June 2020

G1 Therapeutics and Boehringer Ingelheim Announce Co-Promotion Agreement for Trilaciclib in Small Cell Lung Cancer in the United States and Puerto Rico

G1 Therapeutics Has Multiple Roadmaps To A Multi-Billion Dollar Market Cap

- G1 to receive $6 million upfront payment, sales royalties and up to $40 million in future milestone payments  - Genor to lead clinical development, regulatory submissions and commercialization of lerociclib in Asia-Pacific

G1 Therapeutics and Genor Biopharma Announce Exclusive License Agreement for Lerociclib in Asia-Pacific Region

Epizyme

If you have cash to spare, these cancer stocks are set to soar.

2 Top Cancer Treatment Stocks to Buy in June

Corcept Therapeutics

Dynavax Technologies

ImmunoGen

Kadmon Hlds

Supernus Pharmaceuticals

Vertex Pharmaceuticals

As investors begin to turn their attention away from Covid-19 and the novel coronavirus, these biotech stocks present excellent opportunities.

7 Great Biotech Stocks to Buy and Hold Now

G1 Therapeutics (GTHX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

How G1 Therapeutics (GTHX) Stock Stands Out in a Strong Industry

- Non-dilutive capital to support commercialization and additional development of trilaciclib - Non-dilutive capital to support commercialization and additional development of trilaciclib

G1 Therapeutics Announces Flexible Credit Financing for Up to $100 Million with Hercules Capital

Atara Biotherapeutics

Homology Medicines

Viking Therapeutics

Bull market or bear market, one fact remains unwavering: Biotech stocks represent the ultimate risk/reward plays.

7 Biotech Stocks Wall Street Says Will Double or More

G1 Therapeutics, Inc. (GTHX) CEO Mark Velleca on Q1 2020 Results - Earnings Call Transcript

- Jack Bailey appointed to Board of Directors-  Soma Gupta joins as Chief Commercial Officer-  Company reports inducement grant under Nasdaq Listing Rule 5635 (c)(4)

G1 Therapeutics Announces Appointment of New Board Member and Chief Commercial Officer

G1 Therapeutics, Inc. (GTHX) CEO Mark Velleca on Q4 2019 Results - Earnings Call Transcript

RESEARCH TRIANGLE PARK, N.C., Feb.  06, 2020  (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq:  GTHX ), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will participate in a fireside chat at the Guggenheim Healthcare Talks: Oncology Day. The fireside chat will take place on Thursday, February 13, 2020 at 1:00 p.m. ET at the St. Regis Hotel in New York, NY.

News for G1 Therapeutics Stock (GTHX)